RxDoctor Payments Data

James Turbett, MD

Family Medicine · Mentor, OHNPI 1730156621

Payments from drug & device makers

$2,959in general payments, 2019–2025

Across 154 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$440
  • Novo Nordisk$326
  • Phathom Pharmaceuticals, Inc.$309
  • Lilly USA, LLC$271
  • Pfizer$268
  • Amgen$230
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,959 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$91,065
Medicare patients
303
Services billed
1,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide78$100,845
OzempicSemaglutide76$84,558
FarxigaDapagliflozin Propanediol73$73,882
EliquisApixaban27$30,875
JardianceEmpagliflozin22$21,004
TrulicityDulaglutide20$20,647
XareltoRivaroxaban15$14,539
JanuviaSitagliptin Phosphate11$11,799
Novolog FlexpenInsulin Aspart13$9,356
Fiasp FlextouchInsulin Aspart (Niacinamide)11$5,793
Tresiba Flextouch U-100Insulin Degludec11$5,438
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,246
Atorvastatin Calcium605$4,470
SynthroidLevothyroxine Sodium62$3,246
Levothyroxine Sodium327$3,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$271$121,49298 claims
Novo NordiskOzempic$326$84,55876 claims
AstraZenecaFarxiga$440$73,88273 claims
PfizerEliquis$268$30,87527 claims
Johnson & JohnsonXarelto$11$14,53915 claims
MerckJanuvia$51$11,79911 claims
AbbVieSynthroid$207$3,24662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Mentor

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →